Timing note: The event date provided—August 4, 2026—is today, not tomorrow. This is therefore a pre-results preview assuming DuPont has not yet released results.
DuPont enters 2Q with a relatively clear setup: management delivered a better-than-guided 1Q, raised 2026 guidance, and set a specific 2Q framework. The key question is less whether DD can meet its prior 2Q numbers than whether it can demonstrate that the drivers behind the 1Q beat—healthcare growth, mix, productivity, and price realization—remain durable despite softer construction markets and a still-complicated supply-chain/logistics backdrop.
The bar set by management is:
| Metric | 2Q26 company guide | 1Q26 actual |
|---|---|---|
| Net sales | ~$1.80B | $1.681B |
| Organic growth | ~3% | 2% |
| Operating EBITDA | ~$430M | $414M |
| Operating EBITDA margin | ~23.9% | 24.6% |
| Adjusted EPS* | ~$1.77 | ~$1.65 |
*DuPont’s May guidance was stated before the June 24 1-for-3 reverse stock split. Accordingly, the originally guided 2Q adjusted EPS of $0.59 equates to about $1.77 on the post-split basis; its prior $2.35–$2.40 full-year adjusted-EPS range equates to approximately $7.05–$7.20 per post-split share.
Healthcare & Water Technologies is DD’s highest-margin segment and the clearest source of above-market growth. In 1Q, segment organic sales grew 3%, with healthcare up high single digits organically, led by medical packaging and biopharma. Segment EBITDA margin expanded 110 bps to 30.3%.
For 2Q, management guided segment organic growth to the mid-single digits, supported by medical-device, biopharma, and industrial-water demand. Investors should focus on whether:
Read-through: A clean Water recovery and continued healthcare strength would reinforce the view that 2026 organic growth is driven by end-market demand rather than merely price and FX.
Diversified Industrials was approximately flat organically in 1Q. The segment’s margin still expanded 110 bps to 22.9%, reflecting favorable mix and productivity.
Management’s 2Q outlook calls for low-single-digit organic growth, with:
The notable earnings debate is whether DD can keep generating margin expansion while its construction-exposed businesses remain soft. A low-single-digit organic-growth result in Diversified Industrials accompanied by further margin expansion would be constructive, because it would validate the ongoing 80/20 and productivity work rather than relying solely on volume growth.
Management raised full-year guidance in May partly because it expected to offset about $90M of incremental input costs associated with the Middle East conflict through pricing and surcharges. It indicated that roughly $25M of price would occur in 2Q, with fuller price realization in the second half.
Importantly, management explicitly anticipated a sequential 2Q margin decline versus 1Q from:
That is consistent with the ~23.9% implied 2Q EBITDA margin versus 24.6% in 1Q. Thus, a modest sequential margin decline should not itself be viewed negatively. The more meaningful question is whether price capture, input costs, and mix perform better or worse than that known bridge.
Bullish outcome: price realization ramps faster than expected, costs ease, or underlying productivity more than offsets the timing headwinds.
Bearish outcome: inflation/logistics costs outpace realized surcharges, or customer resistance delays price realization.
DD’s May full-year outlook was:
| Metric | FY26 guidance |
|---|---|
| Net sales | $7.155B–$7.215B |
| Organic sales growth | ~4%, including ~1% price |
| Operating EBITDA | $1.730B–$1.760B |
| Adjusted EPS, post-split equivalent | ~$7.05–$7.20 |
| Free-cash-flow conversion | >90% |
Management’s original framework implied that first-half sales and EBITDA would represent about 48% of the full-year midpoint, leaving a meaningful second-half acceleration. That makes the outlook for Water project timing, pricing realization, construction demand, and sustained productivity more important than a small 2Q EPS variance.
A reiteration would be acceptable if segment trends are intact. A raise would likely require evidence that healthcare, Water, and margin execution are tracking better than the existing plan—rather than just favorable FX or non-operating benefits.
DuPont completed the Aramids divestiture on April 1 for approximately $1.2B of pre-tax cash proceeds, plus a $300M note receivable and a non-controlling equity interest in the buyer. The company subsequently announced a $275M accelerated share repurchase, after having completed a prior $500M ASR under its $2B authorization.
Investors should listen for:
DD closed at $141.31 on August 3, up roughly 3.1% from its July 31 close but still about 4.3% below its May 5 post-earnings close. That suggests the stock is not pricing an obvious near-term blowout, but investors will likely demand confirmation that the raised full-year guide remains credible.
The most constructive 2Q result would combine:
Conversely, the principal negative setup would be a Water shortfall, more severe construction softness, or margin pressure that indicates pricing is not keeping pace with costs.